Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

AnaptysBio Inc (ANAB) USD0.001

Sell:$29.42 Buy:$29.56 Change: $1.11 (4.02%)
NASDAQ:1.43%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$29.42
Buy:$29.56
Change: $1.11 (4.02%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$29.42
Buy:$29.56
Change: $1.11 (4.02%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation. Its product pipeline includes ANB020 and ANB019, which are being developed to treat severe inflammatory disorders with unmet medical need. The Company's ANB020 product candidate is an antibody that inhibits the activity of interleukin-33, and is used for the treatment of severe adult asthma and severe adult peanut allergy. In addition, the Company is engaged in developing its ANB019 product candidate, an antibody that inhibits the interleukin-36 receptor, for the treatment of rare inflammatory diseases called generalized pustular psoriasis (GPP) and palmoplantar pustular psoriasis (PPP).

Contact details

Address:
10421 Pacific Center Ct Ste 200
SAN DIEGO
92121-4339
United States
Telephone:
+1 (858) 3626295
Website:
https://www.anaptysbio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ANAB
ISIN:
US0327241065
Market cap:
$769.82 million
Shares in issue:
27.37 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • James Topper
    Independent Chairman of the Board
  • Hamza Suria
    President, Chief Executive Officer, Director
  • Dennis Mulroy
    Chief Financial Officer
  • Eric Loumeau
    Chief Operating Officer, General Counsel
  • Paul Lizzul
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.